J&J has unveiled some slightly mixed phase 3 results. Data from a study in adults with treatment-resistant depression showed that flexibly dosed esketamine nasal spray, plus a newly initiated oral ...
NTI says at the start of the Phase 2/3 ASD trial, 62% of patients in the NTI164 arm were receiving treatment for their anxiety/depression, compared to 43% of patients in the placebo arm.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback